Clinical trials: Neoplasms, Germ Cell and Embryonal
Brain and Central Nervous System Tumors
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01013285
- Testing
- bevacizumab, temozolomide, external beam radiation therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Melanoma
A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001
Patients who were previously enrolled in Study IMM-101-001 and who provided informed consent were eligible to participate in this study.
- Trial name
- NCT01559818
- Testing
- IMM-101
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Immodulon Therapeutics Ltd
Rhabdomyosarcoma, Melanoma
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Open label, non-randomized, multi-center, within-subject comparative study to evaluate the tolerability and the diagnostic utility of Lymphoseek with optional comparison to VBD in pediatric subjects with melanoma…
- Trial name
- NCT02509598
- Testing
- Tc99m tilmanocept, Vital Blue Dye (optional), Lymph Node Mapping
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cardinal Health 414, LLC
Glioma
Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
Background: Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years.
- Trial name
- NCT05413304
- Testing
- Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
This is an ongoing Phase 2, open-label, multicenter, non-randomized study of MEDI4736 (durvalumab) in subjects with glioblastoma (GBM) enrolled into 5 non-comparative cohorts.
- Trial name
- NCT02336165
- Testing
- Durvalumab, Standard radiotherapy, Bevacizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Ludwig Institute for Cancer Research
Brain Tumors, Nervous System Tumors
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
RATIONALE: Armodafinil may help relieve fatigue and improve quality of life in patients with cancer receiving radiation therapy to the brain.
- Conditions
- Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue
- Trial name
- NCT01032200
- Testing
- Armodafinil
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Melanoma
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Combination therapy is becoming more and more general in the treatment of oncological diseases. In this clinical trial combination the standard immunotherapeutic treatment; the programmed death 1 (PD-1) regulatory antibody…
- Trial name
- NCT03047928
- Testing
- Nivolumab, PD-L1/IDO peptide vaccine
- Where
- 2 sites in Denmark
- Volunteers
- 48 people
- Sponsor
- Inge Marie Svane
Pheochromocytoma, Paraganglioma
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
- Trial name
- NCT00458952
- Testing
- Ultratrace Iobenguane (MIBG) I 131
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Melanoma
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma
The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.
- Trial name
- SUMMIT-1 (NCT01006252)
- Testing
- Tasisulam-sodium, Paclitaxel
- Where
- 122 sites in United States, Australia and 16 more
- Volunteers
- 336 people
- Sponsor
- Eli Lilly and Company
Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Trial name
- NCT01950390
- Testing
- Bevacizumab, Ipilimumab
- Where
- 482 sites in United States
- Volunteers
- 169 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Neuroblastoma, CNS Metastases
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to…
- Conditions
- Neuroblastoma, CNS Metastases, Leptomeningeal Metastases
- Trial name
- NCT03275402
- Testing
- 131I-omburtamab
- Where
- 8 sites in United States, Denmark and 2 more
- Volunteers
- 52 people
- Sponsor
- Y-mAbs Therapeutics
Brain Metastases
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
- Trial name
- NCT03075072
- Testing
- Whole brain radiation, Stereotactic radiation (SRS)
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- Brigham and Women's Hospital
Glioma
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
The investigators have developed a phase I/II clinical trial to evaluate the effect of rhIL-7-hyFc on lymphocyte counts in patients with high grade glioma (HGG).
- Trial name
- NCT03687957
- Testing
- rhIL-7-hyFc, Temozolomide, Radiation therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Recurrent Melanoma, Stage IIA Melanoma
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
This phase II trial is studying how well saracatinib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT00669019
- Testing
- saracatinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
MIBG With Dinutuximab +/- Vorinostat
131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease.
- Trial name
- NCT03332667
- Testing
- 131I-MIBG, Dinutuximab, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Glioblastoma, Glioblastoma Multiforme
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults.
- Trial name
- XACT-Fe-GBM-01 (NCT04900792)
- Testing
- Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Bryan Allen
Neuroblastoma, Opsoclonus-myoclonus
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus.
- Trial name
- NCT00202930
- Testing
- anti-CD20 (Rituximab)
- Volunteers
- 4 people
- Sponsor
- Jean M. Tersak, M.D.
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
This phase III trial compares the effect of telotristat ethyl and the current standard of care somatostatin analog therapy or somatostatin analog therapy alone in treating patients with neuroendocrine tumor that has spread to…
- Trial name
- NCT04810091
- Testing
- Questionnaire Administration, Telotristat Ethyl
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Glioblastoma, Recurrent Adult Brain Tumor
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery.
- Conditions
- Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
- Trial name
- NCT01814813
- Testing
- HSPPC-96, bevacizumab
- Where
- 417 sites in United States
- Volunteers
- 90 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.